1
|
Ambati SR, Patel JL, Chandrakar K, Sarkar U, Penta S, Banerjee S, Varma RS. One-pot, Three-component Synthesis of Novel Coumarinyl-Pyrazolo[3,4-b]pyridine-3-Carboxylate Derivatives Using [AcMIm]FeCl4 as Recyclable Catalyst. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2022.133623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
2
|
Chinthaparthi RR, Chittiboena VL, Jorepalli S, Gangireddy CSR. Green synthesis and anticancer activity of tetrahydrodipyrazolo[3,4‐b:4′,3′‐
e
]pyridines catalyzed by phospho sulfonic acid. J Heterocycl Chem 2021. [DOI: 10.1002/jhet.4241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
| | | | - Sumalatha Jorepalli
- Division of Pharmaceutical Chemistry Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam Tirupati India
| | - Chandra Sekhar Reddy Gangireddy
- Department of Organic & Bioorganic Chemistry Sri Venkateswara Degree & PG College Kadapa India
- Department of Fire Chemistry Section, State Key Laboratory of Fire Science University of Science and Technology of China Hefei China
| |
Collapse
|
3
|
Ibrahim TS, Hawwas MM, Taher ES, Alhakamy NA, Alfaleh MA, Elagawany M, Elgendy B, Zayed GM, Mohamed MFA, Abdel-Samii ZK, Elshaier YAMM. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. Bioorg Chem 2020; 105:104352. [PMID: 33080494 DOI: 10.1016/j.bioorg.2020.104352] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 09/23/2020] [Accepted: 10/04/2020] [Indexed: 12/15/2022]
Abstract
PDE5 targeting represents a new and promising strategy for apoptosis induction and inhibition of tumor cell growth due to its over-expression in diverse types of human carcinomas. Accordingly, we report the synthesis of series of pyrazolo[3,4-d]pyrimidin-4-one carrying quinoline moiety (11a-r) with potential dual PDE5 inhibition and apoptotic induction for cancer treatment. These hybrids were structurally elucidated and characterized with variant spectroscopic techniques as 1H NMR, 13C NMR and elemental analysis. The assessment of their anticancer activities has been declared. All the rationalized compounds 11a-r have been selected for their cytotoxic activity screening by NCI against 60 cell lines. Compounds 11a, 11b, 11j and 11k were the most active hybrids. Among all, compound 11j was further selected for five dose tesing and it displayed outstanding activity with strong antitumor activity against the nine tumor subpanels tested with selectivity ratios ranging from 0.019 to 8.3 at the GI50 level. Further, the most active targets 11a, b, j and k were screened for their PDE5 inhibitory activity, compound 11j (with IC50 1.57 nM) exhibited the most potent PDE5 inhibitory activity. Moreover, compound 11j is also showed moderate EGFR inhibition with IC50 of 5.827 ± 0.46 µM, but significantly inhibited the Wnt/β-catenin pathway with IC501286.96 ± 12.37 ng/mL. In addition, compound 11j induced the intrinsic apoptotic mitochondrial pathway in HepG2 cells as evidenced by the lower expression levels of the anti-apoptotic Bcl-2 protein, and the higher expression of the pro-apoptotic protein Bax, p53, cytochrome c and the up-regulated active caspase-9 and caspase-3 levels. All results confirmed by western blotting assay. Compound 11j exhibit pre G1 apoptosis and cell cycle arrest at G2/M phase. In conclusion, hybridization of quinoline moiety with the privileged pyrazolo[3,4-d]pyrimidinon-4-one structure resulted in highly potent anticancer agent, 11j, which deserves more study, in particular, in vivo and clinical investiagtions, and it is expected that these results would be applied for more drug discovery process.
Collapse
Affiliation(s)
- Tarek S Ibrahim
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Center of Excellence for Drug Research & Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
| | - Mohamed M Hawwas
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
| | - Ehab S Taher
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
| | - Nabil A Alhakamy
- Center of Excellence for Drug Research & Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Mohamed A Alfaleh
- Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Mohamed Elagawany
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
| | - Bahaa Elgendy
- Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO 63110, USA; Center for Clinical Pharmacology, Washington University School of Medicine and St. Louis College of Pharmacy, St. Louis, MO 63110, USA; Chemistry Department, Faculty of Science, Benha University, Benha 13518, Egypt
| | - Gamal M Zayed
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University at Assiut, Assiut, Egypt; Al-Azhar Centre of Nanosciences and Applications (ACNA), Assiut, Egypt
| | - Mamdouh F A Mohamed
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, 82524 Sohag, Egypt
| | - Zakaria K Abdel-Samii
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
| | - Yaseen A M M Elshaier
- Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, 32958 Menoufia, Egypt
| |
Collapse
|
4
|
Huang XF, Dong YH, Wang JH, Ke HM, Song GQ, Xu DF. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett 2020; 30:127097. [DOI: 10.1016/j.bmcl.2020.127097] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 03/04/2020] [Accepted: 03/04/2020] [Indexed: 12/23/2022]
|
5
|
Ji Y, Li L, Zhu G, Zhou Y, Lu X, He W, Gao L, Rong L. Efficient reactions for the synthesis of pyrazolo[3,4‐
b
]pyridine and pyrano[2,3‐
c
]pyrazole derivatives from
N
‐methyl‐1‐(methylthio)‐2‐nitroethen‐1‐amine. J Heterocycl Chem 2020. [DOI: 10.1002/jhet.3903] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Yifan Ji
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Li Li
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Guangzhou Zhu
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Ya Zhou
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Xinchi Lu
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Wenjing He
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Lijiu Gao
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| | - Liangce Rong
- Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials; School of Chemistry and Materials ScienceJiangsu Normal University Xuzhou China
| |
Collapse
|
6
|
Liu L, Xu H, Ding S, Wang D, Song G, Huang X. Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease. Brain Res Bull 2019; 153:223-231. [PMID: 31493542 DOI: 10.1016/j.brainresbull.2019.09.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 08/18/2019] [Accepted: 09/01/2019] [Indexed: 01/21/2023]
Abstract
Alzheimer's disease (AD), characterized by a progressive impairment of memory and cognition, is a major health problem in both developing and developed countries. Currently, no drugs can reverse the progression of AD. Phosphodiesterase 5 (PDE5) is a critical component of the cyclic guanosine monophosphate/protein kinase G (cGMP/PKG) signaling pathway in neurons, the inhibition of which has produced neuroprotective effects, and PDE5 inhibitors have recently been thought to be potential therapeutic agents for AD. In this paper, we summarized the outstanding progress that has been made in PDE5 inhibitors as anti-AD agents with encouraging results in animal studies, clinical trials and the investigations on the underlying mechanisms. The novel PDE5 inhibitors reported recently in the treatment of AD were also reviewed and discussed.
Collapse
Affiliation(s)
- Li Liu
- School of Pharmaceutical Engineering & Life Science, Changzhou University, Changzhou, Jiangsu 213164, China
| | - Huang Xu
- School of Pharmaceutical Engineering & Life Science, Changzhou University, Changzhou, Jiangsu 213164, China
| | - Shumin Ding
- School of Pharmaceutical Engineering & Life Science, Changzhou University, Changzhou, Jiangsu 213164, China
| | - Dongyan Wang
- Department of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu 225009, China
| | - Guoqiang Song
- School of Pharmaceutical Engineering & Life Science, Changzhou University, Changzhou, Jiangsu 213164, China.
| | - Xianfeng Huang
- School of Pharmaceutical Engineering & Life Science, Changzhou University, Changzhou, Jiangsu 213164, China.
| |
Collapse
|
7
|
Bollenbach M, Lugnier C, Kremer M, Salvat E, Megat S, Bihel F, Bourguignon JJ, Barrot M, Schmitt M. Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. Eur J Med Chem 2019; 177:269-290. [DOI: 10.1016/j.ejmech.2019.05.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 04/30/2019] [Accepted: 05/07/2019] [Indexed: 12/13/2022]
|
8
|
Aly AA, El-Emary TI, Mourad AFE, Khallaf Alyan Z, Bräse S, Nieger M. 5-Carbohydrazide and 5-carbonylazide of pyrazolo[3,4- b]pyridines as reactive intermediates in the synthesis of various heterocyclic derivatives. JOURNAL OF CHEMICAL RESEARCH 2019. [DOI: 10.1177/1747519819861625] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
5-Carbohydrazides and 5-carbonylazides of pyrazolo[3,4- b]pyridines are used to synthesize new heterocyclic derivatives. Some unexpected behaviors are observed in the reactions of the above two species. The structures of the obtained compounds are proved by spectroscopic studies together with elemental and X-ray structure analyses.
Collapse
Affiliation(s)
- Ashraf A Aly
- Chemistry Department, Faculty of Science, Minia University, El-Minia, Egypt
| | - Talaat I El-Emary
- Department of Chemistry, Faculty of Science, Assiut University, Assiut, Egypt
| | | | | | - Stefan Bräse
- Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany
| | - Martin Nieger
- Department of Chemistry, University of Helsinki, Helsinki, Finland
| |
Collapse
|
9
|
Kumar SV, Muthusubramanian S, Perumal S. Recent Progress in the Synthesis of Pyrazolopyridines and Their Derivatives. ORG PREP PROCED INT 2019. [DOI: 10.1080/00304948.2018.1542517] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Sundaravel Vivek Kumar
- Department of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai – 625021, Tamil Nadu, India
| | - Shanmugam Muthusubramanian
- Department of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai – 625021, Tamil Nadu, India
| | - Subbu Perumal
- Department of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai – 625021, Tamil Nadu, India
| |
Collapse
|
10
|
Liu J, Maisonial-Besset A, Wenzel B, Canitrot D, Baufond A, Chezal JM, Brust P, Moreau E. Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes. Eur J Med Chem 2017; 136:548-560. [PMID: 28544981 DOI: 10.1016/j.ejmech.2017.03.091] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Revised: 03/03/2017] [Accepted: 03/26/2017] [Indexed: 12/20/2022]
Abstract
The increasing incidence of Alzheimer's disease (AD) worldwide is a major public health problem. Current treatments provide only palliative solutions with significant side effects. Therefore, new efficient treatment options and novel early diagnosis tools are urgently needed. Recently, strong pre-clinical evidences suggested that phosphodiesterase 5 (PDE5) may be clinically relevant both as biomarker and drug-target in AD. In this study, we intended to develop a new radiofluorinated tracer for the visualisation of PDE5 in brain using PET imaging. Based on currently known PDE5 inhibitors, a series of novel fluorinated compounds bearing a quinoline core have been synthesised via multi-steps reaction pathways. Their affinity for PDE5 and selectivity over other PDE families have been investigated. According to the data collected from this in vitro screening, fluorinated derivatives 24a, b bearing a fluoroethoxy group at the C-3 position of the quinoline core appeared to be the most promising structures and will be further radiolabelled with fluorine-18 for in vitro and in vivo evaluations as PET radiotracer for neuroimaging of PDE5.
Collapse
Affiliation(s)
- Jianrong Liu
- Univ. Clermont Auvergne, INSERM, UMR 1240, IMOST, F-63005 Clermont-Ferrand, France.
| | | | - Barbara Wenzel
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Dept. of Neuroradiopharmaceuticals, Permoserstrasse 15, 04318 Leipzig, Germany.
| | - Damien Canitrot
- Univ. Clermont Auvergne, INSERM, UMR 1240, IMOST, F-63005 Clermont-Ferrand, France.
| | - Ariane Baufond
- Univ. Clermont Auvergne, INSERM, UMR 1240, IMOST, F-63005 Clermont-Ferrand, France.
| | - Jean-Michel Chezal
- Univ. Clermont Auvergne, INSERM, UMR 1240, IMOST, F-63005 Clermont-Ferrand, France.
| | - Peter Brust
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Dept. of Neuroradiopharmaceuticals, Permoserstrasse 15, 04318 Leipzig, Germany.
| | - Emmanuel Moreau
- Univ. Clermont Auvergne, INSERM, UMR 1240, IMOST, F-63005 Clermont-Ferrand, France.
| |
Collapse
|
11
|
Sakamoto T, Koga Y, Hikota M, Matsuki K, Mochida H, Kikkawa K, Fujishige K, Kotera J, Omori K, Morimoto H, Yamada K. 8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors. Bioorg Med Chem Lett 2015; 25:1431-5. [DOI: 10.1016/j.bmcl.2015.02.041] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Revised: 02/10/2015] [Accepted: 02/16/2015] [Indexed: 10/23/2022]
|
12
|
Gunasekaran P, Perumal S, Menéndez JC, Mancinelli M, Ranieri S, Mazzanti A. Axial Chirality of 4-Arylpyrazolo[3,4-b]pyridines. Conformational Analysis and Absolute Configuration. J Org Chem 2014; 79:11039-50. [DOI: 10.1021/jo502047n] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Pethaiah Gunasekaran
- Department
of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai 625 021, Tamil Nadu, India
| | - Subbu Perumal
- Department
of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai 625 021, Tamil Nadu, India
| | - J. Carlos Menéndez
- Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad Complutense, 28040 Madrid, Spain
| | - Michele Mancinelli
- Department
of Industrial Chemistry “Toso Montanari”, University of Bologna, Viale Risorgimento 4, 40136 Bologna, Italy
| | - Silvia Ranieri
- Department
of Industrial Chemistry “Toso Montanari”, University of Bologna, Viale Risorgimento 4, 40136 Bologna, Italy
| | - Andrea Mazzanti
- Department
of Industrial Chemistry “Toso Montanari”, University of Bologna, Viale Risorgimento 4, 40136 Bologna, Italy
| |
Collapse
|
13
|
Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: Scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation. Bioorg Med Chem Lett 2014; 24:5175-80. [DOI: 10.1016/j.bmcl.2014.09.082] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 09/23/2014] [Accepted: 09/27/2014] [Indexed: 11/20/2022]
|
14
|
Gunasekaran P, Prasanna P, Perumal S. l-Proline-catalyzed three-component domino reactions for the synthesis of highly functionalized pyrazolo[3,4-b]pyridines. Tetrahedron Lett 2014. [DOI: 10.1016/j.tetlet.2013.11.016] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Peculiarities of cyclization of ethyl 2-ethoxymethylene-3-oxo-3-(polyfluoroalkyl)propionates with 3-amino-5-hydroxypyrazole. J Fluor Chem 2013. [DOI: 10.1016/j.jfluchem.2013.01.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
16
|
Gunasekaran P, Indumathi S, Perumal S. l-Proline-catalyzed three-component domino reactions in the regioselective synthesis of novel densely functionalized pyrazolo[3,4-b]pyridines. RSC Adv 2013. [DOI: 10.1039/c3ra00136a] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
17
|
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. Eur J Med Chem 2012; 60:285-94. [PMID: 23313637 DOI: 10.1016/j.ejmech.2012.12.009] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2012] [Revised: 11/29/2012] [Accepted: 12/04/2012] [Indexed: 01/10/2023]
Abstract
Phosphodiesterase type 5 (PDE5) mediates the degradation of cGMP in a variety of tissues including brain. Recent studies have demonstrated the importance of the nitric oxide/cGMP/cAMP-responsive element-binding protein (CREB) pathway to the process of learning and memory. Thus, PDE5 inhibitors (PDE5Is) are thought to be promising new therapeutic agents for the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory loss. To explore this possibility, a series of quinoline derivatives were synthesized and evaluated. We found that compound 7a selectively inhibits PDE5 with an IC(50) of 0.27 nM and readily crosses the blood brain barrier. In an in vivo mouse model of AD, compound 7a rescues synaptic and memory defects. Quinoline-based, CNS-permeant PDE5Is have potential for AD therapeutic development.
Collapse
|
18
|
Emelina EE, Petrov AA, Borissova AO, Filyukov DV, Antipin MY. The interplay of hydrogen bonds in the solid state structure of NH-pyrazoles bearing cyano and amino substituents. J Mol Struct 2012. [DOI: 10.1016/j.molstruc.2012.01.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
19
|
Guercio G, Castoldi D, Giubellina N, Lamonica A, Ribecai A, Stabile P, Westerduin P, Dams R, Nicoletti A, Rossi S, Bismara C, Provera S, Turco L. Overall Synthesis of GSK356278: Quick Delivery of a PDE4 Inhibitor Using a Fit-for-Purpose Approach. Org Process Res Dev 2010. [DOI: 10.1021/op1001148] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Giuseppe Guercio
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Damiano Castoldi
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Nicola Giubellina
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Alessandro Lamonica
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Arianna Ribecai
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Paolo Stabile
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Pieter Westerduin
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Riet Dams
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Anna Nicoletti
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Sara Rossi
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Claudio Bismara
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Stefano Provera
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| | - Lucilla Turco
- Synthetic Chemistry, Analytical Science, PPSE, Technical Sourcing Group, Chemical Development Department, and Analytical Chemistry, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, Verona, Italy
| |
Collapse
|
20
|
Zhang LJ, Shi DX, Li JR. Simultaneous Synthesis of Pyrazolopyridines and Pyrazolopyrimidinones Under Microwave Irradiation. SYNTHETIC COMMUN 2009. [DOI: 10.1080/00397910902883629] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Hamblin JN, Angell TDR, Ballantine SP, Cook CM, Cooper AWJ, Dawson J, Delves CJ, Jones PS, Lindvall M, Lucas FS, Mitchell CJ, Neu MY, Ranshaw LE, Solanke YE, Somers DO, Wiseman JO. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 2008; 18:4237-41. [PMID: 18539455 DOI: 10.1016/j.bmcl.2008.05.052] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2008] [Revised: 05/13/2008] [Accepted: 05/14/2008] [Indexed: 11/28/2022]
Affiliation(s)
- J Nicole Hamblin
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Pissarnitski D. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6. Med Res Rev 2006; 26:369-95. [PMID: 16388517 DOI: 10.1002/med.20053] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The role of phosphodiesterase type 5 (PDE5) in the mechanism of male erection has been well understood, and several drugs inhibiting this enzyme are being used for the treatment of erectile dysfunction (ED). Discovery of inhibitors with improved selectivity versus other PDE isozymes could lead to drugs with improved safety profile. Achievement of selectivity versus PDE6, co-inhibition of which results in disturbances of color perception, remains the most challenging aspect of current drug discovery programs. The present review describes several case studies, where significant (>100 fold) selectivity versus PDE6 has been attained via investigation of structure-activity relationships (SAR). Special attention is given to the chemical routes leading to novel chemotypes and allowing efficient exploration of their SAR's. Strategies for attaining inhibitor selectivity discussed below may be applicable for other drug discovery programs.
Collapse
|
24
|
|
25
|
Fadel S, Hajbi Y, Rakib EM, Khouili M, Pujol MD, Guillaumet G. Condensation of 2‐Pyrone with 3‐Aminopyrazolone. A Novel Synthesis of Pyrazolo[3,4‐b]pyridines. SYNTHETIC COMMUN 2004. [DOI: 10.1081/scc-120038500] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Synthesis of novel hydropyrazolopyridine derivatives in solvent-free conditions via benzotriazole methodology. Tetrahedron 2004. [DOI: 10.1016/j.tet.2004.07.028] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
27
|
Bi Y, Stoy P, Adam L, He B, Krupinski J, Normandin D, Pongrac R, Seliger L, Watson A, Macor JE. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. Bioorg Med Chem Lett 2004; 14:1577-80. [PMID: 15006407 DOI: 10.1016/j.bmcl.2003.12.090] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2003] [Accepted: 12/16/2003] [Indexed: 11/29/2022]
Abstract
In a continuing effort to discover novel chemotypes as potent and selective PDE5 inhibitors for the treatment of male erectile dysfunction (ED), we have found that 4-benzylaminoquinoline derivatives are very potent and selective PDE5 inhibitors. Some compounds in this series had PDE5 IC(50)'s as low as 50 pM. While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. Substitutents at the C3-position can incorporate a variety of different groups. The synthesis and primary structure-activity relationship of this new series of potent PDE5 inhibitors are described.
Collapse
Affiliation(s)
- Yingzhi Bi
- Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Since the early 1980s, research on the mechanisms of penile erection has done much to clarify erectile physiology and pathophysiology. More recent studies have identified the importance of neurochemical mediators in erection. These include the nitric oxide-cyclic guanosine monophosphate (cGMP) cell-signaling system-a complex molecular pathway that mediates smooth muscle relaxation in the corpus cavernosum. Phosphodiesterase 5 (PDE5) inactivates cGMP, which terminates nitric oxide-cGMP-mediated smooth muscle relaxation. Inhibition of PDE5 is expected to enhance penile erection by preventing cGMP degradation. Development of pharmacologic agents with this effect has closely paralleled the emerging science. The prototype of this new therapeutic class of PDE5 inhibitors is sildenafil, which was approved for treatment of erectile dysfunction in 1998. Tadalafil and vardenafil are new agents in this class. These agents have demonstrated improvement in erectile function and have been shown to be well tolerated in diverse populations comprising thousands of men worldwide. Profiles of these 3 PDE5 inhibitors are reviewed herein.
Collapse
Affiliation(s)
- Raymond C Rosen
- Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, USA.
| | | |
Collapse
|
29
|
Haning H, Niewöhner U, Bischoff E. Phosphodiesterase type 5 (PDE5) inhibitors. PROGRESS IN MEDICINAL CHEMISTRY 2003; 41:249-306. [PMID: 12774696 DOI: 10.1016/s0079-6468(02)41007-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Helmut Haning
- BAYER AG Pharmaceutical Business Group, Medicinal Chemistry, D-42096 Wuppertal, Germany
| | | | | |
Collapse
|
30
|
Sui Z, Guan J, Macielag MJ, Jiang W, Qiu Y, Kraft P, Bhattacharjee S, John TM, Craig E, Haynes-Johnson D, Clancy J. Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors. Bioorg Med Chem Lett 2003; 13:761-5. [PMID: 12639576 DOI: 10.1016/s0960-894x(02)01036-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A series of N(2)-furoyl and N(2)pyrimidinyl beta-carbolines was discovered to possess potent inhibitory activity against PDE5. During the synthesis we developed a tandem resin quenching protocol, which allowed us to synthesize large number of target compounds in a rapid fashion. Representative compounds exhibit superior selectivity to sildenafil versus other isozymes of PDEs, and demonstrated in vivo efficacy in increasing introcavernosal pressure in dogs.
Collapse
Affiliation(s)
- Zhihua Sui
- Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, Raritan, NJ 08869, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002; 1:674-82. [PMID: 12209148 DOI: 10.1038/nrd893] [Citation(s) in RCA: 221] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas. This review summarizes recent clinical trials with PDE5 inhibitors, advances in medicinal chemistry, and other activities and potential applications of this class of compounds.
Collapse
Affiliation(s)
- David P Rotella
- Hopewell Discovery Chemistry, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA.
| |
Collapse
|
32
|
Chapter 6. Phosphodiesterase 5 inhibitors. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2002. [DOI: 10.1016/s0065-7743(02)37007-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
33
|
Kopp M, Lancelot JC, Dallemagne P, Rault S. Synthesis of novel pyrazolopyrrolopyrazines, potential analogs of sildenafil. J Heterocycl Chem 2001. [DOI: 10.1002/jhet.5570380506] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|